Fumihiko Hirai

A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L

Fumihiko Hirai, Takeharu Yamanaka, Kenichi Taguchi et al. · Annals of Oncology · 2014 · 128 citations · Full text

Advanced Thymic Carcinoma, Medicine, Pathology +8

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

Takashi Seto, Taito Esaki, Fumihiko Hirai et al. · Cancer Chemotherapy and Pharmacology · 2013 · 101 citations

Dose-escalation Study, Radiation Medicine, Medicine +10

Clinical impact of probiotics on the efficacy of <scp>anti‐PD</scp>‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting

Kazuki Takada, Mototsugu Shimokawa, Shinkichi Takamori et al. · International Journal of Cancer · 2021 · 85 citations · Full text

Probiotic, Treatment Weighting, Cell Lung Cancer +13

Role of surgical resection for patients with limited disease-small cell lung cancer

Tomoyoshi Takenaka, Mitsuhiro Takenoyama, Eiko Inamasu et al. · Lung Cancer · 2015 · 78 citations

Surgical Oncology, Surgical Resection, Medicine +7

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib

Gouji Toyokawa, Fumihiko Hirai, Eiko Inamasu et al. · Journal of Thoracic Oncology · 2014 · 76 citations · Full text

Both Crizotinib, Secondary Mutations, Genetic Disorder +8